How many stem-cell trials for Chronic Kidney Disease are recruiting right now?
Right now 9 of 88 records (10%) carry recruiting status; the rest are completed, finished enrolling or stopped. Snapshot 2026-08-29.
Who these studies will actually take
Studies specify an eGFR band, proteinuria thresholds and stable background therapy, and exclude people already on dialysis or awaiting transplant. The window is narrow: too early and decline is too slow to measure, too late and there is too little kidney left to protect.
The studies currently enrolling
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05018845 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2021-11-06 |
| NCT04592640 — Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis | Early Phase 1 | Recruiting | 9 | The First Affiliated Hospital with Nanjing Medical Universit | 2018-09-17 |
| NCT07275788 — A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) | Phase 1 | Recruiting | 15 | Regend Therapeutics | 2026-01-08 |
| NCT05525507 — Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants | Phase 1 | Recruiting | 10 | University of California, Los Angeles | 2022-12-21 |
| NCT07607197 — Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET) | Phase 1, Phase 2 | Recruiting | 10 | Hospital Universitari Vall d'Hebron Research Institute | 2024-02-01 |
| NCT06752577 — Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disea | n/a | Recruiting | 75 | Mayo Clinic | 2024-12-22 |
| NCT04392206 — AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses | Phase 1 | Recruiting | 15 | Houssam Farres, M.D. | 2020-05-15 |
| NCT07592000 — Breakthrough - T1DM and Chronic Kidney Disease | Phase 1, Phase 2 | Recruiting | 10 | University of Chicago | 2027-04-29 |
What recruiting does and does not mean
Recruiting means a sponsor has an approved protocol and is looking for participants who meet specific criteria. It does not mean the therapy is on sale, that you qualify, or that earlier studies were positive. Records are also left as recruiting after enrolment stalls, so the contact block on the registry page matters more than the label.
Sites sit in 28 countries, led by United States. Travelling for a trial rarely works unless the site has confirmed in writing that it can enrol non-residents and fund the follow-up schedule.
Who is running the studies here
Lead sponsors appearing most often for this condition. Useful for one specific check: whether the entity quoting research at you appears anywhere in it.
- Fred Hutchinson Cancer Center — 13 registered records
- Mayo Clinic — 7 registered records
- Children's Oncology Group — 3 registered records
- University of California, Los Angeles — 2 registered records
- University of California, San Francisco — 2 registered records
- Northwestern University — 2 registered records
Frequently asked
How many stem-cell trials for Chronic Kidney Disease are recruiting right now?
9 of 88 registered records (2026-08-29).
Can I join one of these trials?
Only if you meet the published eligibility criteria and the site confirms capacity. Start from the registry record's contact block, not from a clinic advertisement.
Do trials charge participants?
Trial participation is normally free of charge for the intervention under study; some studies even reimburse travel. Payment demands invert that relationship and should stop the conversation.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Chronic Kidney Disease: cell-therapy evidence and registered trials
- How much does stem cell therapy for Chronic Kidney Disease cost? (2026)
- Chronic Kidney Disease stem cell therapy — your questions answered (2026)
- Chronic Kidney Disease: cell-therapy evidence by therapy class
- MSC vs HSCT for Chronic Kidney Disease: what the registries show